igf-1 lr3 results gains IGF1-LR3 Peptide IGF-1 LR3 Peptide Therapy in
Description
Okouchi M, Okayama N, Aw TY
DOI: 10.3389/fendo.2019.00249 37
Award Recognised: National IP Award 2024 winner Indias Top MSME for Patent Filing and Commercialisation by the Ministry of Commerce & Industry
In the case of GSAO, a reversible renal toxicity described in preclinical studies at the maximal tolerated dose was not observed in human during clinical Phase I (Tsimberidou et al., 2009
